Monday, April 20, 2026 – Tuesday, April 21 - (MedPage Today) -- Adults whose type 2 diabetes was treated with GLP-1 receptor agonists were more than likely to develop cognitive impairment over 10 years than their counterparts not treated with GLP-1 agents, a propensity-matched retrospective...
Monday, April 20, 2026 – Tuesday, April 21 - One in six couples worldwide face infertility issues but there is hope for those who are trying for pregnancy. Dr. Rekha Kumar, endocrinologist at New York Presbyterian Weill Cornell Medical Center, joins TODAY to break down how long it should take to get pregnant at different age ranges before seeking medical help, why some people saw increased fertility after being on weight loss drugs, and more.
Monday, April 20, 2026 – Tuesday, April 21 - A new study identified several overlooked side effects of GLP-1 drugs through self-reporting among Reddit users. Image Credit: Fiordaliso/Getty Images
A recent study found various “hidden” side effects of GLP-1 drugs like Ozempic, including chills, hot flashes, and irregular periods.
The researchers used self-reported Reddit data to examine the real-world effects of these medications.
Monday, April 20, 2026 – Monday, April 20 - Photo Illustration by Thomas Levinson/The Daily Beast/BravoThe Real Housewives of Salt Lake City is TV’s best soap opera, week after week offering twists more shocking than secret twins and characters returning from the dead. That’s because it’s all real, happening in the most haunted suburb in the continental United States.Where else do two women connect over knowing the long-lost birth father of one’s child? Is there another city where women squabble over body positivity in a parking lot off the side of a snowy mountain? Surely, there’s no other place on Earth where Lisa Barlow could come across anywhere near a voice of reason.
Monday, April 20, 2026 – Monday, April 20 - GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of health: cardiorespiratory fitness. While these medications help people shed fat, they also strip away vital muscle mass raising concerns about long-term heart health, physical function, and mortality. The researchers urge combining treatment with exercise, protein intake, and possibly future drugs to avoid hidden downsides of rapid weight loss.
Monday, April 20, 2026 – Monday, April 20 - Ozempic’s weight loss benefits might come at the cost of muscle strength, even if muscle size remains relatively stable. This raises significant concerns for older adults, who are already at risk for muscle loss and reduced mobility. Researchers stress the urgent need for human clinical trials to understand these effects fully.
Monday, April 20, 2026 – Monday, April 20 - Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight regain. Tufts University chemists have created a new multi-target compound that goes beyond the usual GLP-1, GIP, and glucagon approaches by adding a fourth hormone, PYY. This “quadruple-action” design aims to deliver weight loss results on par with bariatric surgery—up to 30%—without invasive procedures, and could change the future of obesity treatment.
Monday, April 20, 2026 – Monday, April 20 - Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to reduced appetite and stronger feelings of fullness. In a study of more than 400 patients, roughly one in five experienced heightened taste sensitivity, and many reported being less hungry and more easily satisfied.
Monday, April 20, 2026 – Monday, April 20 - Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who qualifies for the drug.
Monday, April 20, 2026 – Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels. With a safety profile consistent with existing treatments, experts see it as a breakthrough for patients preferring oral options.